Casdin Capital, a director and 10% holder, purchased 175,000 shares of GeneDx for $7.45M, signaling confidence in the genomics diagnostics leader. This trade marks the largest insider purchase in the company's history, potentially supporting the stock as it recovers from a severe 50% year-to-date decline.
Price context
The stock has rallied 14.88% over the past five days but remains down 50.65% over the last 90 days. It is currently trading 73.81% below its 52-week high of $170.87 and 38.44% above its 52-week low of $32.325.
Catalysts to watch
- •The largest insider purchase in the company's history on May 18, 2026.
- •A May 23, 2026, Motley Fool article citing a 34% growth in test volumes.
- •A May 22, 2026, Barrons article noting activist investor interest.
Risks
- •The stock carries high volatility with a beta of 2.07 and a short interest of 27.36%.
- •Recent news indicates a securities investigation and a Q1 2026 earnings miss that led to a guidance cut.
AI-generated context from public data. Not investment advice. Verify before trading.